Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL

Neurology

Volumn 81, Issue 3, 2013, Pages 256-263

  Farrell, Brian T ^a   Hamilton, Bronwyn E ^a   Dosa, Edit ^a   Rimely, Endre ^a   Nasseri, Morad ^a   Gahramanov, Seymur ^a   Lacy, Cynthia A ^a   Frenkel, Eugene P ^b   Doolittle, Nancy D ^a   Jacobs, Paula M ^c   Neuwelt, Edward A ^a,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERUMOXYTOL; GADOLINIUM; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ARTICLE; BRAIN BLOOD VOLUME; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CLINICAL FEATURE; DEMYELINATING DISEASE; DEMYELINATION; DIAGNOSTIC PROCEDURE; ENCEPHALITIS; ENCEPHALOMYELITIS; HUMAN; INFLAMMATION; IRON TRANSPORT; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LYMPHOCYTIC INFILTRATION; LYMPHOPROLIFERATIVE DISEASE; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM;

ADULT; AGED; BRAIN; BRAIN DISEASES; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; FERRIC COMPOUNDS; HUMANS; INFLAMMATION; LYMPHOMA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NANOPARTICLES;

EID: 84881286653     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31829bfd8f     Document Type: Article

References (30)

1. Abla O Weitzman S Blay JY et al Primary CNSL in children and adolescents: a descriptive analysis from the International Primary CNSL Collaborative Group (IPCG) Clin Cancer Res 2011 17 346-352
2. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNSL. J Clin Oncol 2005;23:5034-5043
3. Blay JY. Primary cerebral non-Hodgkin lymphoma in nonimmunocompromised subjects [in French]. Bull Cancer 1997;84:976-980
4. Cavaliere R, Petroni G, Lopes MB, Schiff D. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer 2010;116: 863-870
5. Doolittle ND, Abrey LE, Shenkier TN, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNSL Collaborative Group Report. Blood 2008;111:1085-1093
6. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993;119:1093-1104
7. Herrlinger U, Schabet M, Clemens M, et al. Clinical presentation and therapeutic outcome in 26 patients with primary CNSL. Acta Neurol Scand 1998;97:257-264
8. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg 1988;68:835-853
9. Rock JP, Cher L, Hochberg FH, Test AB. Central nervous system lymphomas in AIDS and non-AIDS patients. In: Youmans JR, editor. Neurological Surgery, 4th ed. Philadelphia: WB Saunders; 1995.
10. Angelov L, Doolittle ND, Kraemer DF, et al. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNSL: a multi-institutional experience. J Clin Oncol 2009;27:3503-3509
11. Buhring U, Herrlinger U, Krings T, Thiex R, Weller M, Kuker W. MRI features of primary central nervous system lymphomas at presentation. Neurology 2001;57:393-396
12. law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt AW. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002;222:715-721
13. Lee IH, Kim ST, Kim HJ, Kim KH, Jeon P, Byun HS. Analysis of perfusion weighted image of CNSL. Eur J Radiol 2010;76:48-51
14. Tang YZ, Booth TC, Bhogal P, Malhotra A, Wilhelm T. Imaging of primary central nervous system lymphoma. Clin Radiol 2011;66:768-777
15. Morris PG, Abrey LE. Therapeutic challenges in primary CNSL. Lancet Neurol 2009;8:581-592
16. Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY. CNS complications of radiotherapy and chemotherapy. Lancet 2009;374:1639-1651
17. Neuwelt EA Hamilton BE Varallyay CG et al Ultrasmall superparamagnetic iron oxides (USPIOs) a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Kidney Int 2009 75 465-474
18. Dosa E, Guillaume DJ, Haluska M, et al. Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol. Neuro Oncol 2011;13: 251-260
19. Hamilton BE, Nesbit GM, Dosa E, et al. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging. AJR Am J Roentgenol 2011;197:981-988
20. Ostergaard L, Sorensen AG, Kwong KK, Weisskoff RM, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: experimental comparison and preliminary results. Magn Reson Med 1996;36:726-736
21. Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 2007;188:1447-1474
22. Gahramanov S, Raslan AM, Muldoon LL, et al. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrastenhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys 2011;79:514-523
23. Gahramanov S, Muldoon LL, Li X, Neuwelt EA. Improved perfusion Mr imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol. Radiology 2011;261:796-804
24. Gahramanov S, Muldoon LL, Varallyay CG, et al. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibilityweighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival. Radiology 2013;266:842-852
25. Weinstein JS, Varallyay CG, Dosa E, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies: a review. J Cereb Blood Flow Metab 2010;30:15-35
26. Schroeter M, Saleh A, Wiedermann D, Hoehn M, Jander S. Histochemical detection of ultrasmall superparamagnetic iron oxide (USPIO) contrast medium uptake in experimental brain ischemia. Magn Reson Med 2004;52:403-406
27. De Keyser J, Steen C, Mostert JP, Koch MW. Hypoperfusion of the cerebral white matter in multiple sclerosis: possible mechanisms and pathophysiological significance. J Cereb Blood Flow Metab 2008;28:1645-1651
28. Feraheme [package insert]. Lexington, MA: AMAG Pharmaceuticals, Inc.; 2012.
29. Neuwelt EA, Varallyay CG, Manninger S, et al. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery 2007;60: 601-611
30. Tourdias T, Roggerone S, Filippi M, et al. Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxideenhanced MR imaging. Radiology 2012;264:225-233